Target Price | $495.30 |
Price | $428.59 |
Potential | 15.57% |
Number of Estimates | 10 |
10 Analysts have issued a price target IDEXX Laboratories 2025 . The average IDEXX Laboratories target price is $495.30. This is 15.57% higher than the current stock price. The highest price target is $566.00 32.06% , the lowest is $435.00 1.50% . | |
A rating was issued by 15 analysts: 6 Analysts recommend IDEXX Laboratories to buy, 7 to hold and 2 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the IDEXX Laboratories stock has an average upside potential 2025 of 15.57% . Most analysts recommend the IDEXX Laboratories stock at Hold. |
10 Analysts have issued a sales forecast IDEXX Laboratories 2024 . The average IDEXX Laboratories sales estimate is $3.9b . This is 0.85% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $3.9b 1.02% , the lowest is $3.9b 0.70% .
This results in the following potential growth metrics:
2023 | $3.7b | 8.72% |
---|---|---|
2024 | $3.9b | 5.92% |
2025 | $4.1b | 6.81% |
2026 | $4.5b | 8.53% |
2027 | $4.9b | 8.62% |
7 Analysts have issued an IDEXX Laboratories EBITDA forecast 2024. The average IDEXX Laboratories EBITDA estimate is $1.3b . This is 4.59% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $1.4b 11.32% , the lowest is $1.2b 0.25% .
This results in the following potential growth metrics and future EBITDA Margins:
2023 | $1.2b | 22.17% |
---|---|---|
2024 | $1.3b | 7.26% |
2025 | $1.4b | 10.15% |
2026 | $1.5b | 8.35% |
2027 | $1.7b | 10.28% |
2023 | 32.98% | 12.37% |
---|---|---|
2024 | 33.40% | 1.27% |
2025 | 34.44% | 3.11% |
2026 | 34.38% | 0.17% |
2027 | 34.91% | 1.54% |
11 IDEXX Laboratories Analysts have issued a net profit forecast 2024. The average IDEXX Laboratories net profit estimate is $857m . This is 0.87% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $864m 1.64% , the lowest is $853m 0.39% .
This results in the following potential growth metrics and future Net Margins:
2023 | $825m | 25.28% |
---|---|---|
2024 | $857m | 3.88% |
2025 | $981m | 14.41% |
2026 | $1.1b | 13.13% |
2027 | $1.3b | 13.63% |
2023 | 22.54% | 15.23% |
---|---|---|
2024 | 22.11% | 1.92% |
2025 | 23.68% | 7.10% |
2026 | 24.69% | 4.27% |
2027 | 25.83% | 4.62% |
11 Analysts have issued a IDEXX Laboratories forecast for earnings per share. The average IDEXX Laboratories <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is $10.45 . This is 0.87% higher than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is $10.53 1.64% , the lowest is $10.40 0.39% .
This results in the following potential growth metrics and future valuations:
2023 | $10.06 | 25.28% |
---|---|---|
2024 | $10.45 | 3.88% |
2025 | $11.96 | 14.45% |
2026 | $13.53 | 13.13% |
2027 | $15.37 | 13.60% |
Current | 41.35 | 15.25% |
---|---|---|
2024 | 41.01 | 0.82% |
2025 | 35.85 | 12.58% |
2026 | 31.69 | 11.60% |
2027 | 27.88 | 12.02% |
Based on analysts' sales estimates for 2024, the IDEXX Laboratories stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 9.23 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 9.05 .
This results in the following potential growth metrics and future valuations:
Current | 9.31 | 17.54% |
---|---|---|
2024 | 9.23 | 0.88% |
2025 | 8.64 | 6.38% |
2026 | 7.96 | 7.86% |
2027 | 7.33 | 7.93% |
Current | 9.13 | 17.53% |
---|---|---|
2024 | 9.05 | 0.85% |
2025 | 8.47 | 6.38% |
2026 | 7.81 | 7.86% |
2027 | 7.19 | 7.93% |
IDEXX Laboratories...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.